Recombinant Mouse M-CSF (carrier-free)

Pricing & Availability
Regulatory Status
Other Names
Ave. Rating
Submit a Review
Product Citations
M-NFS-60 cell proliferation induced by mouse M-CSF.
  • a_M-CSF_Mouse_031512
    M-NFS-60 cell proliferation induced by mouse M-CSF.
  • b_MCSF_Mouse_RECOM_BA_020923
    Recombinant mouse M-CSF induces proliferation of M-NFS-60 cells in a dose dependent manner. BioLegend’s protein was compared side-by-side to a competitor’s equivalent product.
Cat # Size Price Quantity Check Availability Save
576402 10 µg 81€
Check Availability

Need larger quantities of this item?
Request Bulk Quote
576404 25 µg 123€
Check Availability

Need larger quantities of this item?
Request Bulk Quote
576406 100 µg 400€
Check Availability

Need larger quantities of this item?
Request Bulk Quote
576408 500 µg 1688€
Check Availability

Need larger quantities of this item?
Request Bulk Quote

M-CSF was first characterized as a glycoprotein that induces monocyte and macrophage colony formation from precursors in murine bone marrow cultures. M-CSF binds CD14+ monocytes and promotes the survival/proliferation of peripheral blood monocytes. In addition, M-CSF enhances inducible monocyte functions including phagocytic activity, microbial killing, and cytotoxicity for tumor cells as well as induces the synthesis of inflammatory cytokines such as IL-1, TNFα, and IFNγ in monocytes.

Multiple CSF1 mRNA species have been described that arise from alternative splicing in exon 6 and the alternative use of the 3’ end of exons 9 or 10. As a result, two distinct CSF1 protein products are encoded by these transcripts: a cell-surface or membrane-bound form of CSF1 (mCSF1) and a soluble form (sCSF1). Uterine sCSF1 is highly increased during pregnancy. On the contrary, uterine mCSF1 remains low during pregnancy. High levels of M-CSF have been associated to different pathologies such as pulmonary fibrosis and atherosclerosis.

M-CSF binds to its receptor M-CSFR, and this receptor is shared by a second ligand, IL-34. Mouse M-CSF and IL-34 exhibit cross-species specificity, both bind to the human and mouse M-CSF receptors. IL-34 can regulate myeloid development and substitute for CSF-1 in vivo. IL-34 has overlapping but not identical biological activities as M-CSF.

Product Details
Technical Data Sheet (pdf)

Product Details

Mouse M-CSF, amino acids Lys33-Glu262 (Accession# NM_001113530.1) was expressed in 293E cells.
Molecular Mass
The 251 amino acid recombinant protein has a predicted molecular mass of approximately 28.2 kD. The DTT-reduced and non-reduced protein migrate at approximately 50 kD and 100 kD respectively by SDS-PAGE. The N-terminal contains a His9-(SGGG)2-IEGR-tag.
>98%, as determined by Coomassie stained SDS-PAGE.
0.22 µm filtered protein solution is in PBS.
Endotoxin Level
Less than 0.01 ng per µg cytokine as determined by the LAL method.
10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
ED50 =2 - 6 ng/ml, corresponding to a specific activity of 1.6 - 5 x 105 units/mg, as determined by M-NFS60 cell proliferation induced by mouse M-CSF in a dose dependent manner.


Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at

Product Citations
  1. Jiang Z, et al. 2021. J Clin Invest. 131: . PubMed
  2. Miki S, et al. 2021. Sci Rep. 11:22469. PubMed
  3. Yokozeki Y, et al. 2021. Biomed Res Int. 2021:7988320. PubMed
  4. Kuo PC, et al. 2021. Brain Commun. 3:fcab187. PubMed
  5. Duarte C, et al. 2022. J Cell Mol Med. 26:2841. PubMed
  6. Pan L, et al. 2022. Mol Immunol. 147:101. PubMed
  7. Pannunzio B, et al. 2022. Cells. 11: . PubMed
  8. Woods PS, et al. 2022. Elife. 11: . PubMed
  9. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  10. Tamura T, et al. 2022. Biomedicines. 10: . PubMed
  11. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  12. Moerland JA, et al. 2023. Antioxidants (Basel). 12: . PubMed
  13. Slusarczyk P, et al. 2023. Elife. 12: . PubMed
  14. Mirji G, et al. 2022. Sci Immunol. 7:eabn0704. PubMed
  15. Choi CHJ, et al. 2022. Elife. 11:. PubMed
  16. Lin Z, et al. 2023. Front Immunol. 14:1077203. PubMed
  17. Reich LA, et al. 2023. Int J Mol Sci. 24:. PubMed
  18. Aaron N, et al. 2022. Life Metab. 1:258. PubMed
  19. Jagodinsky JC, et al. 2022. J Immunother Cancer. 10:. PubMed
  20. Liu TC, et al. 2021. Cell Host Microbe. 29:988. PubMed
  21. Meng W, et al. 2021. JCI Insight. 6:. PubMed
  22. Hayes BH, et al. 2020. J Cell Sci. . PubMed
  23. Zhou LJ et al. 2019. Cell Rep. 27(13):3844-3859 . PubMed
  24. Bodduluri SR, et al. 2018. Cancer Immunol Res. 6(3). PubMed
  25. Miller JE, et al. 2020. Front Immunol. 11:108. PubMed
  26. Moon JS, et al. 2021. JCI Insight. 6:. PubMed
  27. Wang Q, et al. 2022. Nat Commun. 13:3022. PubMed
  28. Adachi Y, et al. 2022. Nat Commun. 13:5117. PubMed
  29. Li Y, et al. 2022. J Lipid Res. :100273. PubMed
  30. Torretta S, et al. 2020. Nat Commun. 4.863194444. PubMed
  31. Zhou Y, et al. 2020. Hepatology. 71:1453. PubMed
  32. Feng J, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.71. PubMed
  33. Cox N, et al. 2015. Proc Natl Acad Sci U S A. 112: 8385 - 8390. PubMed
  34. Hammer A, et al. 2016. Proc Natl Acad Sci U S A. 113(49):14109-14114. PubMed
  35. Hu J, et al. 2020. Theranostics. 7.154166667. PubMed
  36. Woo YD, et al. 2020. J Allergy Clin Immunol. . PubMed
  37. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  38. Ikeda S, et al. 2022. Sci Rep. 12:11564. PubMed
  39. Tian J, et al. 2021. EMBO J. 40:e106065. PubMed
  40. Wang X, et al. 2021. Cell Death Differ. 28:3235. PubMed
  41. Lee D, et al. 2021. J Lipid Res. 62:100117. PubMed
  42. Dongre A, et al. 2021. Cancer Discov. 11:1286. PubMed
  43. Dabouz R, et al. 2020. J Neuroinflammation. 0.957638889. PubMed
  44. Miranda K, et al. 2019. Front Immunol. 10:1049. PubMed
  45. Vorselen D, et al. 2021. Elife. 10:. PubMed
  46. Mouton AJ, et al. 2021. J Mol Cell Cardiol. 158:38. PubMed
  47. Thi Tran U, et al. 2019. Commun Biol. 2:2. PubMed
  48. Saika R, et al. 2017. Journal of Neuroinflammation . 10.1186/s12974-017-0884-8. PubMed
  49. Chen Y, et al. 2021. Front Pharmacol. 12:735194. PubMed
  50. Hao Q, et al. 2022. Cells. 11:. PubMed
  51. Zhang T, et al. 2021. Redox Biol. 101930:41. PubMed
  52. Huber R, et al. 2015. PLoS One. 10: 0144338. PubMed
  53. Lu Y, et al. 2020. Immunity. 52:782. PubMed
  54. Li X, et al. 2019. Cell Death Discov. 5:62. PubMed
  55. Hayes BH, et al. 2020. J Cell Sci. 133:00:00. PubMed
  56. Miyamoto T, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  57. Yang Z, et al. 2017. J Biol Chem. 292(4):1178-1186. PubMed
  58. Miranda K, et al. 2018. Int J Obes (Lond). 42:1140. PubMed
  59. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  60. Olmsted-Davis E, et al. 2021. Front Immunol. 12:686769. PubMed
  61. Huffaker TB, et al. 2021. Nat Commun. 12:2620. PubMed
  62. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  63. Schröder A, et al. 2021. Int J Mol Sci. 22:00. PubMed
  64. Nakayama Y, et al. 2020. Proc Natl Acad Sci U S A. 117:14365. PubMed
  65. Wang Y, et al. 2019. Front Cell Infect Microbiol. 9:286. PubMed
  66. Mellal K, et al. 2019. Sci Rep. 9:12903. PubMed
  67. Woods PS, et al. 2020. Am J Respir Cell Mol Biol. 62:243. PubMed
  68. Gomez-Lopez N, et al. 2021. JCI Insight. 6:. PubMed
  69. Davies JM, et al. 2021. Immunol Cell Biol. 99:622. PubMed
  70. Zhao H, et al. 2022. Front Immunol. 13:931087. PubMed
  71. Chen YH, et al. 2022. Arthritis Res Ther. 24:27. PubMed
  72. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  73. Kim SH, et al. 2020. Neoplasia. 1.3375. PubMed

Antigen Details

Disulfide-linked glycosylated homodimer.

M-CSF is broadly expressed in adult mouse tissues. M-CSF is released by fibroblasts, breast cancer cell lines, alveolar macrophages, stromal bone marrow cells, endothelial cells, and mesenchymal cells.

M-CSF is the key regulator of the survival, proliferation, and differentiation of mononuclear phagocytes and plays a central role in the regulation of osteoclastogenesis. CSF-1 also regulates the development of Paneth cells, Langerhans cells, lamina propria dendritic cells, and microglia.
Monocytes, macrophages, mononuclear phagocyte precursors, microglia, proliferating smooth muscle cells, umbilical vein endothelial cells, and breast cancer cell lines.
M-CSFR or CSF1R (CD115)
Cell Type
Embryonic Stem Cells, Hematopoietic stem and progenitors
Biology Area
Cell Biology, Cell Proliferation and Viability, Immunology, Stem Cells
Molecular Family
Cytokines/Chemokines, Growth Factors
Antigen References

1. Kawasaki ES, et al. 1985. Science 230:291.
2. Wei S, et al. 2010. J. Leukocyte Biol. 88:495.
3. MacDonald KP, et al. 2010. Blood 116:3955.
4. Hodge JM, et al. 2011. Plos One 6:e21462.
5. Morandi et al. 2011. Plos One 6:e27450.
6. Erblich B, et al. 2011. Plos One 6:e26317.

Gene ID
12977 View all products for this Gene ID
View information about M-CSF on

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Go To Top Version: 3    Revision Date: 01/17/2017

For Research Use Only. Not for diagnostic or therapeutic use.


This product is supplied subject to the terms and conditions, including the limited license, located at ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.


BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.


8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account